losartan has been researched along with Alzheimer Disease in 12 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| "12 months of treatment with losartan was well tolerated but was not effective in reducing the rate of brain atrophy in individuals with clinically diagnosed mild-to-moderate Alzheimer's disease." | 9.41 | Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial. ( Barnes, J; Ben-Shlomo, Y; Blair, PS; Clegg, SL; Coulthard, E; Fox, NC; Howden, B; Jarutyte, L; Kehoe, PG; Lane, JA; Malone, IB; Mutsaerts, HJ; Nielsen, C; Passmore, P; Sudre, CH; Taylor, J; Thai, NJ; Thomas, DL; Turner, N; Wilkinson, I; Wilson, A, 2021) |
| " We tested the curative potential of the non brain-penetrant ACEi enalapril (3 mg/kg/day) administered for 3 months either alone or in combination with the brain penetrant ARB losartan (10 mg/kg/day) in aged (∼15 months) transgenic mice overexpressing a mutated form of the human amyloid-β protein precursor (AβPP, thereafter APP mice)." | 5.43 | Enalapril Alone or Co-Administered with Losartan Rescues Cerebrovascular Dysfunction, but not Mnemonic Deficits or Amyloidosis in a Mouse Model of Alzheimer's Disease. ( Aboulkassim, T; Hamel, E; Imboden, H; Nicolakakis, N; Ongali, B; Tong, XK, 2016) |
| "12 months of treatment with losartan was well tolerated but was not effective in reducing the rate of brain atrophy in individuals with clinically diagnosed mild-to-moderate Alzheimer's disease." | 5.41 | Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial. ( Barnes, J; Ben-Shlomo, Y; Blair, PS; Clegg, SL; Coulthard, E; Fox, NC; Howden, B; Jarutyte, L; Kehoe, PG; Lane, JA; Malone, IB; Mutsaerts, HJ; Nielsen, C; Passmore, P; Sudre, CH; Taylor, J; Thai, NJ; Thomas, DL; Turner, N; Wilkinson, I; Wilson, A, 2021) |
| " Growing evidence reveal that Angiotensin II (Ang II) contributes to the pathogenesis of Alzheimer disease (AD)." | 3.91 | Angiotensin II triggers autophagy and apoptosis in PC12 cell line: An in vitro Alzheimer's disease model. ( Lin, X; Lu, J; Shi, J; Tian, M; Wu, L; Zhang, Y, 2019) |
| "In studies of dementias and Alzheimer's disease (AD), some studies have shown that antihypertensive drugs, including angiotensin-converting enzyme inhibitors, have some moderate effects on cognitive decline, but that the angiotensin receptor antagonist losartan has a significantly beneficial effect." | 2.42 | Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression. ( Gard, PR, 2004) |
| "Losartan-treated mice (10 mg/kg per day, drinking water, 7 months) received intracerebroventricular (1 month) administration of vehicle or AT2R antagonist PD123319 (1." | 1.56 | AT2R's (Angiotensin II Type 2 Receptor's) Role in Cognitive and Cerebrovascular Deficits in a Mouse Model of Alzheimer Disease. ( Fermigier, A; Hamel, E; Lacalle-Aurioles, M; Royea, J; Trigiani, LJ, 2020) |
| " We tested the curative potential of the non brain-penetrant ACEi enalapril (3 mg/kg/day) administered for 3 months either alone or in combination with the brain penetrant ARB losartan (10 mg/kg/day) in aged (∼15 months) transgenic mice overexpressing a mutated form of the human amyloid-β protein precursor (AβPP, thereafter APP mice)." | 1.43 | Enalapril Alone or Co-Administered with Losartan Rescues Cerebrovascular Dysfunction, but not Mnemonic Deficits or Amyloidosis in a Mouse Model of Alzheimer's Disease. ( Aboulkassim, T; Hamel, E; Imboden, H; Nicolakakis, N; Ongali, B; Tong, XK, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 8 (66.67) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Kehoe, PG | 2 |
| Turner, N | 1 |
| Howden, B | 2 |
| Jarutyte, L | 1 |
| Clegg, SL | 1 |
| Malone, IB | 2 |
| Barnes, J | 1 |
| Nielsen, C | 1 |
| Sudre, CH | 1 |
| Wilson, A | 1 |
| Thai, NJ | 1 |
| Blair, PS | 2 |
| Coulthard, E | 2 |
| Lane, JA | 1 |
| Passmore, P | 1 |
| Taylor, J | 1 |
| Mutsaerts, HJ | 1 |
| Thomas, DL | 2 |
| Fox, NC | 2 |
| Wilkinson, I | 1 |
| Ben-Shlomo, Y | 2 |
| Royea, J | 3 |
| Lacalle-Aurioles, M | 1 |
| Trigiani, LJ | 1 |
| Fermigier, A | 1 |
| Hamel, E | 5 |
| Zhang, L | 1 |
| Tong, XK | 4 |
| Horwood, J | 1 |
| Clement, C | 1 |
| Selman, LE | 1 |
| Baber, H | 1 |
| Lane, A | 1 |
| Passmore, AP | 1 |
| Wilkinson, IB | 1 |
| Tian, M | 2 |
| Lin, X | 1 |
| Wu, L | 1 |
| Lu, J | 1 |
| Zhang, Y | 1 |
| Shi, J | 2 |
| Ongali, B | 3 |
| Nicolakakis, N | 2 |
| Aboulkassim, T | 2 |
| Papadopoulos, P | 1 |
| Rosa-Neto, P | 1 |
| Lecrux, C | 1 |
| Imboden, H | 2 |
| Tanskanen, A | 1 |
| Taipale, H | 1 |
| Koponen, M | 1 |
| Tolppanen, AM | 1 |
| Hartikainen, S | 1 |
| Ahonen, R | 1 |
| Tiihonen, J | 1 |
| Zhu, D | 1 |
| Xie, W | 1 |
| Gard, PR | 1 |
2 reviews available for losartan and Alzheimer Disease
| Article | Year |
|---|---|
Neurovascular and Cognitive failure in Alzheimer's Disease: Benefits of Cardiovascular Therapy.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Cognition Disorders; Humans; Losartan; Sim | 2016 |
Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression.
Topics: Aging; Alzheimer Disease; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inh | 2004 |
2 trials available for losartan and Alzheimer Disease
| Article | Year |
|---|---|
Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial.
Topics: Alzheimer Disease; Atrophy; Brain; Double-Blind Method; Humans; Losartan; Middle Aged; State Medicin | 2021 |
The Rationale and Design of the Reducing Pathology in Alzheimer's Disease through Angiotensin TaRgeting (RADAR) Trial.
Topics: Activities of Daily Living; Alzheimer Disease; Antihypertensive Agents; Atrophy; Blood Pressure Moni | 2018 |
8 other studies available for losartan and Alzheimer Disease
| Article | Year |
|---|---|
AT2R's (Angiotensin II Type 2 Receptor's) Role in Cognitive and Cerebrovascular Deficits in a Mouse Model of Alzheimer Disease.
Topics: Alzheimer Disease; Angiotensin II Type 2 Receptor Blockers; Animals; Anti-Inflammatory Agents; Cogni | 2020 |
Angiotensin IV Receptors Mediate the Cognitive and Cerebrovascular Benefits of Losartan in a Mouse Model of Alzheimer's Disease.
Topics: Alzheimer Disease; Angiotensin II Type 1 Receptor Blockers; Animals; Cerebrovascular Circulation; Co | 2017 |
Angiotensin II triggers autophagy and apoptosis in PC12 cell line: An in vitro Alzheimer's disease model.
Topics: Alzheimer Disease; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Auto | 2019 |
Angiotensin II type 1 receptor blocker losartan prevents and rescues cerebrovascular, neuropathological and cognitive deficits in an Alzheimer's disease model.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Angiotensin II Type 1 Receptor Blockers; Animals; | 2014 |
From prescriptions to drug use periods - things to notice.
Topics: Alzheimer Disease; Citalopram; Diuretics; Dose-Response Relationship, Drug; Drug Labeling; Drug Pres | 2014 |
Enalapril Alone or Co-Administered with Losartan Rescues Cerebrovascular Dysfunction, but not Mnemonic Deficits or Amyloidosis in a Mouse Model of Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloidosis; Analysis of V | 2016 |
Central angiotensin II-induced Alzheimer-like tau phosphorylation in normal rat brains.
Topics: Alzheimer Disease; Angiotensin II; Animals; Brain; Cognition; Dose-Response Relationship, Drug; Enzy | 2012 |
[Blood pressure increases risk for dementia and stroke. Antihypertensive drugs for mental degeneration?].
Topics: Alzheimer Disease; Antihypertensive Agents; Atenolol; Cerebral Infarction; Clinical Trials as Topic; | 2004 |